– USA, MD – MaxCyte, Inc., (Nasdaq: MXCT | LON: MXCT/MXCN) today announced the appointment of Board Member, Dr. Richard Douglas (Ph.D.) as Chair of the Board of Directors, succeeding Dr. Stark Thompson who will not seek re-election. but will remain as a consultant.
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization.
“Since bringing his wealth of experience to the board in 2018, Richard has been a valuable contributor as we sought to list on the Nasdaq. His new role is a natural transition for him to continue the strong, impactful leadership that MaxCyte has enjoyed under Stark’s guidance of the Board since the founding of MaxCyte,” said Founder and CEO, Doug Doerfler. “
He added: “Stark helped set the foundation as we built MaxCyte to be the leading enabling platform technology in cell therapy worldwide. It has been a true honor to work with him and we thank him for his dedication and perspective.”
“It has been an honor to serve on the MaxCyte board. The company is well positioned to continue providing its industry-leading technology to the rapidly expanding cell therapy development pipeline,” added Dr. Thompson.
About Dr. Richard Douglas
Dr. Douglas is a veteran pharmaceutical executive who presently serves as an adviser at RedSky Partners, Chair of the Board of Aldeyra Therapeutics, a director of Novavax Inc., and Chair of the National Advisory Board of Innovation Partnerships at the University of Michigan. He formerly held the role of Senior Vice President of Corporate Development and Corporate Officer at Genzyme Corporation where he led numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. He had previously held scientific and corporate development roles at Integrated Genetics.
“MaxCyte’s ExPERT™ technology and cell engineering expertise is well-known throughout the industry and I’m extremely proud to step into the role of Board Chair on the heels of its first U.S. public offering, which marks a pivotal time in the Company’s history,” said Dr. Douglas.
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development,, and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes three instruments, the ATx, STx,, and GTx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.
For more information: https://maxcyte.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.